Thymosin beta 4 clinical trials have mostly stayed in early phases. Here's what the research shows on safety, results, and FDA status in the U.S.
Thymosin beta 4 clinical trials have been conducted in humans, but nearly all of them stopped at Phase 1 or Phase 2. The peptide has been tested as a gel, an eye drop, and an injection for conditions including dry eye, chronic wounds, and heart damage after a heart attack. No trial has produced an FDA-approved product, and thymosin beta 4 is not approved for human use in the United States.
This article summarizes what those trials studied, what they found, and where the research stands today.
Are There Real Human Clinical Trials on Thymosin Beta 4?
Yes. Most of the human data comes from RegeneRx Biopharmaceuticals, a small US biotech company that developed synthetic versions of the peptide under the names RGN-137, RGN-259, and RGN-352. Academic groups have also run smaller pilot studies, mostly in eye and wound healing.
By contrast, thymosin beta 4 studies performed in mice, rats, and cell cultures are far more numerous than human trials. Animal results are often reported as if they apply to people, and that gap is the main source of confusion online.
Which Conditions Have Been Studied?
- Dry eye disease — a preservative-free eye drop (RGN-259) tested in Phase 2 and Phase 3 trials.
- Neurotrophic keratopathy — a rare corneal condition studied with the same eye drop in a Phase 3 program.
- Epidermolysis bullosa — a topical gel (RGN-137) tested in Phase 2 for a genetic blistering skin disease.
- Chronic skin ulcers — venous stasis and pressure ulcers treated with topical gel in Phase 2 studies.
- Heart attack damage — an injectable form (RGN-352) studied in early-phase trials in patients after myocardial infarction.
- Corneal wound healing — small investigator-led studies using eye drops after surgery or injury.
| Formulation | How it was given | Condition studied | Highest phase reached |
|---|---|---|---|
| RGN-259 | Eye drops | Dry eye disease | Phase 3 |
| RGN-259 | Eye drops | Neurotrophic keratopathy | Phase 3 |
| RGN-137 | Topical gel | Epidermolysis bullosa | Phase 2 |
| RGN-137 | Topical gel | Venous stasis and pressure ulcers | Phase 2 |
| RGN-352 | Injection | Acute myocardial infarction | Phase 1/2 |
No thymosin beta 4 formulation has advanced past Phase 3 or been filed for FDA approval in the United States.
What Did the Trials Actually Show?
Results have been mixed rather than dramatic. One Phase 3 dry eye trial did not meet its primary endpoint, although a subgroup of patients with more severe disease showed improvement. The neurotrophic keratopathy program reported positive changes in corneal healing measures, and the topical gel produced wound closure in some epidermolysis bullosa and ulcer patients.
Several important limits apply to all of this data:
- Sample sizes were small, often fewer than 100 patients per study.
- Treatment periods were short, usually weeks to a few months.
- Some trials were open-label, meaning patients and doctors knew who received treatment.
- RegeneRx has not completed a large, pivotal trial that would support FDA approval in the US.
The FDA did grant orphan drug designation to RGN-137 for epidermolysis bullosa, which creates incentives for development but is not the same as approval.
Is Thymosin Beta 4 FDA-Approved?
Thymosin beta 4 is not FDA-approved for any human use in the United States. It is not a legal dietary ingredient, so anything marketed as a thymosin beta 4 supplement is typically sold as a "research chemical" and labeled for laboratory use only.
That labeling matters. Research chemicals are not required to meet the purity, sterility, or dosing standards applied to prescription drugs, and independent testing has repeatedly found mislabeled peptides in this market.
Safety and Side Effects Reported in Trials
In published trials, the most common side effects were mild and local — eye irritation with drops, injection site reactions with the injectable form, and occasional headache. No serious safety signal emerged in the early-phase cardiac work.
Those results come from short studies in carefully selected patients. Long-term safety, effects during pregnancy, and interactions with other medications have not been established, and anyone considering the peptide should talk with a healthcare professional first.
How It Compares With Other Research Peptides
| Peptide | Human trial status | Notes |
|---|---|---|
| Thymosin beta 4 | Phase 1–3, mixed results | No FDA approval; eye, skin, and cardiac programs |
| BPC-157 | No completed US human trials | Animal and in vitro data only |
| AOD-9604 | Phase 2 completed | Obesity trial did not show meaningful weight loss versus placebo |
| Cagrilintide | Phase 3 | Amylin analog studied for obesity and type 2 diabetes |
For context, aod 9604 clinical trials reached Phase 2 in obesity, and cagrilintide clinical trials have moved into large Phase 3 programs. Thymosin beta 4 sits in the middle: it has real human data, but far less than a drug that is close to market.
Common Claims That Outrun the Evidence
Marketing pages often describe thymosin beta 4 benefits in ways the trials do not support. The peptide has been studied for tissue repair and inflammation, not for general wellness, anti-aging, or athletic performance.
Thymosin beta 4 hair growth is another popular claim. Hair follicle studies have been conducted mainly in mice and in laboratory cultures, and no published human trial has shown that the peptide regrows hair in people with pattern baldness.
Dosing, Forms, and What's Sold Online
There is no established human thymosin beta 4 dosage. Trials used specific formulations — a 0.1% eye drop, a topical gel, and an injectable — that are not available to consumers, and doses were set by the study sponsor rather than by any public standard.
Online vendors publish their own numbers, and forums repeat them. Many of those charts are copied between websites with no clinical source behind them, which is why the numbers rarely agree.
What This Means If You're Considering It
- No thymosin beta 4 product is FDA-approved for human use.
- The strongest human evidence is early-phase and mixed.
- Products sold online are unregulated research chemicals.
- Any decision about a peptide should involve a licensed clinician.
The honest summary is that thymosin beta 4 is a promising laboratory peptide with a modest, incomplete clinical record. It has not earned a place in routine medical care, and it should not be treated as a proven therapy.
Frequently Asked Questions
Has thymosin beta 4 been tested in humans?
Yes. Thymosin beta 4 has been tested in human trials for dry eye disease, neurotrophic keratopathy, epidermolysis bullosa, chronic skin ulcers, and heart attack damage. Most of those studies were Phase 1 or Phase 2, with a few Phase 3 eye trials.
Is thymosin beta 4 FDA-approved?
No. Thymosin beta 4 is not FDA-approved for any human use in the United States. Products sold online are labeled as research chemicals for laboratory use only and are not legal dietary supplements.
What did thymosin beta 4 clinical trials find?
Results were mixed. One Phase 3 dry eye trial missed its primary endpoint, though a severely affected subgroup improved, and eye trials in neurotrophic keratopathy reported positive corneal healing changes. Skin and cardiac studies showed signals of benefit but were small and short.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.